First forgive me for coping the attached post, it's not my style but this
time I did it because it's important to keep the continuity. Second, I'm not
currently on Lactnet and only reading post here and there from the archives so I
have not read every post on this tread.

Carol Schlef, thank you for pointing out that J & J has definitely made major
corporate changes over the past several years.  I've been watching how that
have morally and ethical evolved with the influence of wonderful people like
Marshall Klaus and others.  Their changes have been because they care and that
is a breath of fresh air.

I also learned the connection between J & J and Janseen several years ago and
called Tom Hale to discuss seeing if we could get Janseen to apply to FDA to
have domperidone approved in US. Tom called Janssen in Itlay and spoke to
Janssen Cilag's VP who told him it had been discussed at many board meeting, even
the past board meeting and was considered too expensive to apply to US FDA and
not likely to of any profit to Janssen.  Part of the reason it would not be a
good move for Janssen is because of patent laws.  It's not a new drug, it's
been around so long that other companies could make the generic form.  So,
Janssen would lay out the big buck (extremely large bucks) to apply to FDA to get
it approved and then US pharmaceuticals could make the generic and Janssen
would likely lose money on the whole deal not even breaking even.

Warm regards,
Pat Lindsey, IBCLC - Lactation Services www.PatLC.com
Pediatrics Plus' Lactation Consultant www.pedsplus.com
webmaster/Florida Lactation Consultant Association www.flca.info

"What good fortune for governments that the people do not think."Adolf Hitler



<<From:         Carol Schlef <[log in to unmask]>
Subject:      Re: Johnson & Johnson connection w/formula companies?
Content-Type: text/plain; charset=us-ascii
Hi all,

I have to jump in here....first of all, in the interests of disclosure, I
have done consulting work for J&J for the past 2-3 years, and am on their
Pediatric Advisory Board.

Before signing a contract with them, however, I went over their annual
report, websites, etc. with a fine-toothed comb.

The IBFAN information is VERY outdated (1999). J&J has been out of the bottle
and pacifier business for several years. In fact, the latest IBFAN report
(just released in the last few weeks) acknowledges that J&J has stopped
selling/manufacturing/marketing infant feeding substitutes. Its only citation is that
their website has a link to www.babycenter.com which sells bottles. It's on
page 86 of the full report:

http://www.ibfan.org/english/pdfs/btr04.pdf


I've already been in communication with the US Director of J&J's Consumer
Products Divison about this infraction, & he is looking into the BabyCenter
issue. Additionally, BabyCenter is NOT "their online store", but a separate
website/company entirely. They have their own advisory board, including Kathleen
Huggins.

J&J no longer partners with Nestle or any baby food manufacturer. In fact,
they have their own "discharge pack" with lotion, etc. and an infant care
booklet. I was asked to edit the section on infant feeding, and while I'm not 100%
happy with its wording, it IS solely about breastfeeding. The only mention of
formula is a 2-sentence blurb under the heading "If you are unable to
breastfeed" or something like that, which basically says discuss your decision with
your doctor.

NONE of J&J's subsidiaries are involved in bottle, formula, or pacifier
production. Janssen and Ortho-McNeil are their primary pharmaceutical companies,
and neither make formula. I spoke with a Janssen rep at an advisory board
meeting a couple of years ago about why Motilium was not available in the US, and
she said it was because it was too costly to play the games with the FDA to get
it approved. I got the impression that there were some competing companies (of
similar products, like Reglan) that were putting up roadblocks, & Janssen
didn't feel it was financially worth their while to fight that particular battle.

If any of you would like to communicate directly with my contact at J&J,
please email me privately, & I'll forward your letters on to him.

Smiles,

Carol

Carol Schlef, RNC, MSW, IBCLC, LCCE


Date:    Tue, 8 Jun 2004 12:02:31 +0200
From:    Heleen Hayes <[log in to unmask]>
Subject: Re: FDA Warns...Domperidone

On 7 Jun 2004 at 22:12, Pat Lindsey, IBCLC wrote:

> I smell a rat.  And, it smells like a formula company.  We are at war
> with big business.  The formula companies and all the pharmaceutical
> companies don't want the US to have higher breastfeeding rates, it's
> not good for their bottom line.  Imagine the reduced antibiotic use on
> infants under one year if we had Sweden's breastfeeding rate.  Sweden
> has the highest breastfeeding rate and the lowest infant mortility.
> We are 27th in infant mortility! What does that say about our
> wonderful health care system and our country.  Where are our
> priorities?  Making money is number one, not health care and certainly
> not babies.

Janssen Cilag, the company that makes Motillium, is part of Johnsson
& Johnson.
And guess what? According to 'Breaking the Rules' they are good
friends with Nestl=E9:
http://www.ibfan.org/english/codewatch/btr01/JJMAM-en.HTM
--
Heleen Hayes
www.xs4all.nl/~hhayes>>

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html